OBJECTIVES: This study sought to examine the role of lipoprotein-associated phospholipase A₂ (Lp-PLA₂/PLA2G7) in human inflammation and coronary atherosclerosis. BACKGROUND: Lp-PLA₂ has emerged as a potential therapeutic target in coronary heart disease. Data supporting Lp-PLA₂ are indirect and confounded by species differences; whether Lp-PLA₂ is causal in coronary heart disease remains in question. METHODS: We examined inflammatory regulation of Lp-PLA₂ during experimental endotoxemia in humans, probed the source of Lp-PLA₂ in human leukocytes under inflammatory conditions, and assessed the relationship of variation in PLA2G7, the gene encoding Lp-PLA₂, with coronary artery calcification. RESULTS: In contrast to circulating tumor necrosis factor-alpha and C-reactive protein, blood and monocyte Lp-PLA₂ messenger ribonucleic acid decreased transiently, and plasma Lp-PLA₂ mass declined modestly during endotoxemia. In vitro, Lp-PLA₂ expression increased dramatically during human monocyte to macrophage differentiation and further in inflammatory macrophages and foamlike cells. Despite only a marginal association of single nucleotide polymorphisms in PLA2G7 with Lp-PLA₂ activity or mass, numerous PLA2G7 single nucleotide polymorphisms were associated with coronary artery calcification. In contrast, several single nucleotide polymorphisms in CRP were significantly associated with plasma C-reactive protein levels but had no relation with coronary artery calcification. CONCLUSIONS: Circulating Lp-PLA₂ did not increase during acute phase response in humans, whereas inflammatory macrophages and foam cells, but not circulating monocytes, are major leukocyte sources of Lp-PLA₂. Common genetic variation in PLA2G7 is associated with subclinical coronary atherosclerosis. These data link Lp-PLA₂ to atherosclerosis in humans while highlighting the challenge in using circulating Lp-PLA₂ as a biomarker of Lp-PLA₂ actions in the vasculature.
OBJECTIVES: This study sought to examine the role of lipoprotein-associated phospholipase A₂ (Lp-PLA₂/PLA2G7) in humaninflammation and coronary atherosclerosis. BACKGROUND: Lp-PLA₂ has emerged as a potential therapeutic target in coronary heart disease. Data supporting Lp-PLA₂ are indirect and confounded by species differences; whether Lp-PLA₂ is causal in coronary heart disease remains in question. METHODS: We examined inflammatory regulation of Lp-PLA₂ during experimental endotoxemia in humans, probed the source of Lp-PLA₂ in human leukocytes under inflammatory conditions, and assessed the relationship of variation in PLA2G7, the gene encoding Lp-PLA₂, with coronary artery calcification. RESULTS: In contrast to circulating tumor necrosis factor-alpha and C-reactive protein, blood and monocyte Lp-PLA₂ messenger ribonucleic acid decreased transiently, and plasma Lp-PLA₂ mass declined modestly during endotoxemia. In vitro, Lp-PLA₂ expression increased dramatically during human monocyte to macrophage differentiation and further in inflammatory macrophages and foamlike cells. Despite only a marginal association of single nucleotide polymorphisms in PLA2G7 with Lp-PLA₂ activity or mass, numerous PLA2G7 single nucleotide polymorphisms were associated with coronary artery calcification. In contrast, several single nucleotide polymorphisms in CRP were significantly associated with plasma C-reactive protein levels but had no relation with coronary artery calcification. CONCLUSIONS: Circulating Lp-PLA₂ did not increase during acute phase response in humans, whereas inflammatory macrophages and foam cells, but not circulating monocytes, are major leukocyte sources of Lp-PLA₂. Common genetic variation in PLA2G7 is associated with subclinical coronary atherosclerosis. These data link Lp-PLA₂ to atherosclerosis in humans while highlighting the challenge in using circulating Lp-PLA₂ as a biomarker of Lp-PLA₂ actions in the vasculature.
Authors: Robert L Wilensky; Yi Shi; Emile R Mohler; Damir Hamamdzic; Mark E Burgert; Jun Li; Anthony Postle; Robert S Fenning; James G Bollinger; Bryan E Hoffman; Daniel J Pelchovitz; Jisheng Yang; Rosanna C Mirabile; Christine L Webb; LeFeng Zhang; Ping Zhang; Michael H Gelb; Max C Walker; Andrew Zalewski; Colin H Macphee Journal: Nat Med Date: 2008-09-21 Impact factor: 53.440
Authors: Patrick W Serruys; Héctor M García-García; Pawel Buszman; Paul Erne; Stefan Verheye; Michael Aschermann; Henrikus Duckers; Oyvind Bleie; Dariusz Dudek; Hans Erik Bøtker; Clemens von Birgelen; Don D'Amico; Tammy Hutchinson; Andrew Zambanini; Frits Mastik; Gerrit-Anne van Es; Antonius F W van der Steen; D Geoffrey Vince; Peter Ganz; Christian W Hamm; William Wijns; Andrew Zalewski Journal: Circulation Date: 2008-09-01 Impact factor: 29.690
Authors: Jeppe Zacho; Anne Tybjaerg-Hansen; Jan Skov Jensen; Peer Grande; Henrik Sillesen; Børge G Nordestgaard Journal: N Engl J Med Date: 2008-10-30 Impact factor: 91.245
Authors: Lori B Daniels; Gail A Laughlin; Mark J Sarno; Ricki Bettencourt; Robert L Wolfert; Elizabeth Barrett-Connor Journal: J Am Coll Cardiol Date: 2008-03-04 Impact factor: 24.094
Authors: Ji Young Kim; Yae Jung Hyun; Yangsoo Jang; Byoung Kwon Lee; Jey Sook Chae; So Eui Kim; Hyun Yang Yeo; Tae-Sook Jeong; Dong Woon Jeon; Jong Ho Lee Journal: Am J Clin Nutr Date: 2008-09 Impact factor: 7.045
Authors: Brendan J Keating; Sam Tischfield; Sarah S Murray; Tushar Bhangale; Thomas S Price; Joseph T Glessner; Luana Galver; Jeffrey C Barrett; Struan F A Grant; Deborah N Farlow; Hareesh R Chandrupatla; Mark Hansen; Saad Ajmal; George J Papanicolaou; Yiran Guo; Mingyao Li; Stephanie Derohannessian; Paul I W de Bakker; Swneke D Bailey; Alexandre Montpetit; Andrew C Edmondson; Kent Taylor; Xiaowu Gai; Susanna S Wang; Myriam Fornage; Tamim Shaikh; Leif Groop; Michael Boehnke; Alistair S Hall; Andrew T Hattersley; Edward Frackelton; Nick Patterson; Charleston W K Chiang; Cecelia E Kim; Richard R Fabsitz; Willem Ouwehand; Alkes L Price; Patricia Munroe; Mark Caulfield; Thomas Drake; Eric Boerwinkle; David Reich; A Stephen Whitehead; Thomas P Cappola; Nilesh J Samani; A Jake Lusis; Eric Schadt; James G Wilson; Wolfgang Koenig; Mark I McCarthy; Sekar Kathiresan; Stacey B Gabriel; Hakon Hakonarson; Sonia S Anand; Muredach Reilly; James C Engert; Deborah A Nickerson; Daniel J Rader; Joel N Hirschhorn; Garret A Fitzgerald Journal: PLoS One Date: 2008-10-31 Impact factor: 3.240
Authors: Hanrui Zhang; Chenyi Xue; Rhia Shah; Kate Bermingham; Christine C Hinkle; Wenjun Li; Amrith Rodrigues; Jennifer Tabita-Martinez; John S Millar; Marina Cuchel; Evanthia E Pashos; Ying Liu; Ruilan Yan; Wenli Yang; Sager J Gosai; Daniel VanDorn; Stella T Chou; Brian D Gregory; Edward E Morrisey; Mingyao Li; Daniel J Rader; Muredach P Reilly Journal: Circ Res Date: 2015-04-22 Impact factor: 17.367
Authors: Jaume Padilla; Nathan T Jenkins; Sewon Lee; Hanrui Zhang; Jian Cui; Mozow Y Zuidema; Cuihua Zhang; Michael A Hill; James W Perfield; Jamal A Ibdah; Frank W Booth; J Wade Davis; M Harold Laughlin; R Scott Rector Journal: Physiol Genomics Date: 2013-04-16 Impact factor: 3.107
Authors: Jane F Ferguson; Gregory J Matthews; Raymond R Townsend; Dominic S Raj; Peter A Kanetsky; Matthew Budoff; Michael J Fischer; Sylvia E Rosas; Radhika Kanthety; Mahboob Rahman; Stephen R Master; Atif Qasim; Mingyao Li; Nehal N Mehta; Haiqing Shen; Braxton D Mitchell; Jeffrey R O'Connell; Alan R Shuldiner; Weang Kee Ho; Robin Young; Asif Rasheed; John Danesh; Jiang He; John W Kusek; Akinlolu O Ojo; John Flack; Alan S Go; Crystal A Gadegbeku; Jackson T Wright; Danish Saleheen; Harold I Feldman; Daniel J Rader; Andrea S Foulkes; Muredach P Reilly Journal: J Am Coll Cardiol Date: 2013-05-30 Impact factor: 24.094
Authors: Andrea S Foulkes; Gregory J Matthews; Ujjwal Das; Jane F Ferguson; Rongheng Lin; Muredach P Reilly Journal: PLoS One Date: 2013-02-06 Impact factor: 3.240